Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance.

ABSTRACT:

Background

There are scarce data regarding the use of remdesivir in patients with severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) and end-stage renal disease as US Food and Drug Administration cautions against its use in patients with an estimated glomerular filtration rate <30 ml/min/1.73m² unless the potential benefits outweigh the potential risks. We studied the compassionate use and safety profile of remdesivir in patients with end-stage renal disease and moderate to severe SARS-CoV-2 infection.

Methods

We conducted an observational prospective study in 48 dialysis-dependent patients with SARS-CoV-2 infection who received remdesivir as part of institutional treatment protocol. During the treatment period, 100 mg of remdesivir was given 4

SUBMITTER: Aiswarya D 

PROVIDER: S-EPMC7746511 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature